Pulmonology

Wyoming, Louisiana, and Oklahoma have the lowest percentage of population with shots in arms based on state population. Is your state among the other 7?

Encouraging patients to reach out with questions may lead more to roll up their sleeves this season, Tochi Iroku-Malize, MD, told Patient Care.

Tochi Iroku-Malize, MD, discusses the ACIP's updated recommendations for immunization against COVID-19, influenza, and RSV.

ICYMI: A quick look at 7 key drugs FDA-approved in the second quarter for conditions commonly seen in primary care.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

Data from a study performed during the first season the shot was available expand on clinical trial evidence and support the safety of RSVpreF, authors wrote.

Your daily dose of the clinical news you may have missed.

The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.

The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.

The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.

Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.

Your daily dose of the clinical news you may have missed.

mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.

The dual interleukin-4, 13 inhibitor reduced COPD exacerbation rates by as much as 34% for individuals with COPD with type 2 inflammation, Bhatt explains.

FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.

Your daily dose of the clinical news you may have missed.

Pulmonology experts agreed that adopting race-neutral diagnostic and research practices could help mitigate a range of inequities faced by minority populations.

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.

Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.

A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.

The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.

Your daily dose of the clinical news you may have missed.

Nearly 20% of an older cohort with COPD reported anxiety that was subsequently associated with more severe symptoms and acute exacerbations.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.